• Leadership and Structure
• Corporate Governance
• Public Policy
  • Access and Affordability
  • Pricing and Value
  • Health Care Reform
  • Resources
  • Pat the Pill
• History
• Accolades

Pfizer Public Policy: Resources

Access and Affordability

Policies Limiting Choice of Prescription Drugs

• Why Patients Need a Choice of Medicines
• American Journal of Managed Care (72 KB)
• Study by Frank Lichtenberg (59 KB)
• Study by Wilson, Axelson and Tang (66 KB)
• Research by Murawski and Abdelgawad (63 KB)
• Study by Virabhak and Shinogle (68 KB)
• Study by Headen and Masia (61 KB)

Advertising and Promotion

• Prescription Drug Advertising: Empowering Consumers Through Information (89 KB), Pfizer Inc, Economic Realities in Health Care Policy, 2001; Vol. 2, Iss. 1
• Pharmaceutical Marketing and Promotion: Creating Access to Innovation , Pfizer Inc, Economic Realities in Health Care Policy, 2003; Vol. 3, Iss. 1
• Risk Information in Print Advertisements (216 KB), Pfizer comments to the US Food and Drug Administration in the matter of Disclosing Risk Information in Consumer-Directed Print Advertisements, May 7, 2004
• Direct to Consumer Promotional Communications (293 KB), Pfizer comments to the US Food and Drug Administration in the matter of Consumer-Directed Promotion, December 1, 2003
• DTC Benefits Supported By a Strong Data Record (44 KB), Pfizer Inc

• Medicare Prescription Drug Coverage: What Does it Mean for You? (342 KB), Pfizer Inc, 2005
• Medicare Prescription Drug Coverage: Pick the Plan That's Best for You (1.1 MB), Pfizer Inc, 2005
• Ten Things You Need to Know About Medicare Prescription Drug Coverage (238 KB), Pfizer Inc, 2005

Pricing and Value

Intellectual Property

• Delivering on the Promise of Pharmaceutical Innovation: The Need to Maintain Strong and Predictable Property Rights (587 KB), White Paper by the Pharmaceutical Research and Manufacturers Association (PhRMA)
• Intellectual Property Rights and the Pharmaceutical Industry: The Consequence of Incomplete Protection (195 KB), Fraser Institute Report, 1999

Price Controls

• Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation (1.6 MB), U.S. Department of Commerce, December 2004
• Are Rx Price Controls Good for Your Health? (92 KB), The Manhattan Institute, Medical Progress Report, Dec. 2004; No. 1

Importation

• HHS Report on Prescription Drug Importation (5.9 MB), U.S. Dept. of Health and Human Services (HHS), December 2004
• Update on Prescription Drug Prices (102 KB), Arizona Attorney General's Office, September 2002 (PDF file) Report on Prescription Drug Importation U.S. Dept. of Health and Human Services (HHS), December 2004

Generics

• Generic Drug Competition in the U.S. (521 KB), Research Report in Business Briefing: Pharmatech 2003
• Federal Trade Commission Study - Generic Drug Entry Prior to Patent Expiration (3.1 MB), FTC, July 2002

Health Care Reform

How Pfizer is Acting on Its Health Care

• Working to End Health Disparities

The Uninsured

• Uninsured Fact Pack (418 KB), Pfizer Inc, 2004

Last Updated September 2007

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

A

B-D

E-H

I-N

O-P

R-Z

A-B

C

D-E

F-L

M-P

R-U

V-Z